Hepatitis C Recurrence Unaffected by Immunosuppressive Therapy

Strategic Insights -

A recent study from the United States has shed light on the effectiveness of different immunosuppressive regimens in preventing hepatitis C recurrence after liver transplants. The research, conducted by P. Martin and colleagues from the Liver Transplantation Program at Cedars Sinai Medical Center, aimed to investigate whether the choice of calcineurin inhibitor impacts the severity of recurrent hepatitis C. The study involved 79 patients who received either tacrolimus or cyclosporine as their primary immunosuppressant post-transplantation.

Key Takeaways:

  • The study found that the frequency and severity of hepatitis C recurrence were not significantly different between patients treated with tacrolimus and those treated with cyclosporine.
  • While patients treated with cyclosporine had significantly larger increases in median serum HCV RNA levels, no significant differences were observed in histologically-diagnosed HCV recurrence/survival rates between the two treatment arms.
  • The study concluded that the choice of calcineurin inhibitors does not impact the severity of recurrent hepatitis C.
  • The study included 79 patients who were randomized to receive either tacrolimus (38 patients) or cyclosporine (41 patients) as their primary immunosuppressant post-transplantation.
  • The pathologist was blinded to treatment and reviewed serial liver biopsies to assess the cumulative probabilities of histological hepatitis C recurrence at month 12.

Statistics:

  • Month 12 cumulative probabilities of histological hepatitis C recurrence for tacrolimus-treated patients were 0.38.
  • Month 12 cumulative probabilities of histological hepatitis C recurrence for cyclosporine-treated patients were 0.54 (p=0.19).
  • Failure/death rates at month 12 for tacrolimus-treated patients were 0.25.
  • Failure/death rates at month 12 for cyclosporine-treated patients were 0.28 (p=0.789).
  • Median serum HCV RNA levels increased significantly in patients treated with cyclosporine, but not in patients treated with tacrolimus.

Sources:

  • P. Martin et al. "Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: A prospective, randomized trial." Liver Transplant, 2004;10(10):1258-1262.